The process likely requires the involvement of multiple genetic driver alterations intimately linked with prostate cancer progression, effective inhibition of the AR signaling axis, and time to enable the downstream epigenetic effectors to continuously reprogram the transcriptome of cancer cells depending on conditions [47] (Fig. 1). Here, AR is linked to prostate carcinoma.